Majithiya Jayesh B, Balaraman R, Giridhar Rajani, Yadav Mange Ram
Pharmacy Department, Faculty of Technology and Engineering, M.S. University of Baroda, Kalabhavan, Baroda-390001, Gujarat, India.
J Trace Elem Med Biol. 2005;18(3):211-7. doi: 10.1016/j.jtemb.2004.12.001.
The effect of the vanadium complex bis[curcumino]oxovanadium (BCOV) on blood glucose level, serum lipid levels, blood pressure and vascular reactivity were studied in non-diabetic and streptozotocin-induced diabetic (STZ-diabetic) rats and compared to that of vanadyl sulfate. Blood glucose level, serum lipid levels, and blood pressure were significantly increased in STZ-diabetic rats. Vascular reactivity to various agonists such as noradrenaline and acetylcholine were significantly increased in STZ-diabetic rats. Blood glucose and serum lipid levels were restored to normal in STZ-diabetic animals treated with vanadyl sulfate at a concentration of 0.5 mmol/kg/day (p.o.). However, vanadyl sulfate at a concentration of 0.2 mmol/kg/day (p.o.) did not produce any significant change in blood glucose and lipid levels. There was no significant effect of vanadyl sulfate (0.2 or 0.5 mmol/kg/day) treatment on blood pressure and vascular reactivity in STZ-diabetic rats. Vanadyl sulfate significantly reduced the body weight of non-diabetic and STZ-diabetic rats. Moreover, it also caused severe diarrhea in both groups of animals. Treatment with BCOV (0.05, 0.1 and 0.2mmol/kg/day, p.o.) significantly decreased blood glucose level and serum lipids in STZ-diabetic rats. Furthermore, administration of BCOV to STZ-diabetic rats restored the blood pressure and vascular reactivity to agonists to normal. There was no significant change in the body weight of BCOV treated non-diabetic and STZ-diabetic rats. Diarrhea was not observed in both BCOV treated groups. In conclusion, the present study shows that the vanadium complex BCOV has antidiabetic and hypolipedimic effects. In addition, it improves the cardiovascular complications associated with diabetes.
研究了钒配合物双[姜黄素]氧钒（BCOV）对非糖尿病和链脲佐菌素诱导的糖尿病（STZ糖尿病）大鼠血糖水平、血脂水平、血压和血管反应性的影响，并与硫酸氧钒进行了比较。STZ糖尿病大鼠的血糖水平、血脂水平和血压显著升高。STZ糖尿病大鼠对去甲肾上腺素和乙酰胆碱等各种激动剂的血管反应性显著增加。以0.5 mmol/kg/天（口服）的浓度用硫酸氧钒治疗的STZ糖尿病动物的血糖和血脂水平恢复正常。然而，以0.2 mmol/kg/天（口服）的浓度的硫酸氧钒对血糖和血脂水平没有产生任何显著变化。硫酸氧钒（0.2或0.5 mmol/kg/天）治疗对STZ糖尿病大鼠的血压和血管反应性没有显著影响。硫酸氧钒显著降低了非糖尿病和STZ糖尿病大鼠的体重。此外，它还导致两组动物严重腹泻。用BCOV（0.05、0.1和0.2 mmol/kg/天，口服）治疗可显著降低STZ糖尿病大鼠的血糖水平和血脂。此外，给STZ糖尿病大鼠施用BCOV可使血压和对激动剂的血管反应性恢复正常。用BCOV治疗的非糖尿病和STZ糖尿病大鼠的体重没有显著变化。在两个用BCOV治疗的组中均未观察到腹泻。总之，本研究表明钒配合物BCOV具有抗糖尿病和降血脂作用。此外，它改善了与糖尿病相关的心血管并发症。
